Autres langues TiumBio Co., Ltd.

Actions

A321550

KR7321550006

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 20/06/2024			Varia. 5j.	Varia. 1 janv.
5 930 ^KRW	-0,84 %		-14,06 %	-39,30 %

01/06	Tiumbio Co. Présente les résultats intermédiaires de la phase 1B de Tu2218 en association avec le pembrolizumab lors de la réunion annuelle de l'Asco 2024	CI
08/05	TiumBio Co. annonce des résultats préliminaires positifs de l'essai de phase 2A de Merigolix chez des patientes souffrant de douleurs modérées à sévères associées à l'endométriose	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting	01/06
TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	08/05
Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	26/03
TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer	11/03
TiumBio Co., Ltd. announced that it has received KRW 19.9999947 billion in funding from SK Chemicals Co.,Ltd	28/12
TiumBio Co., Ltd. announced that it expects to receive funding from SK Chemicals Co.,Ltd	20/12
TiumBio Co., Ltd. announced that it has received KRW 18.5 billion in funding from a group of investors	23/10/23
TiumBio Co., Ltd.(KOSDAQ:A321550) dropped from S&P Global BMI Index	18/09/23
TiumBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23
Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd	08/08/22
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21/10/21
Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.	27/09/21
Protium Science announced that it expects to receive KRW 6 billion in funding from TiumBio Co., Ltd.	15/09/21
TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	03/09/21
TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding	31/08/21
TiumBio Co., Ltd. announced that it expects to receive KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	27/08/21
SK Plasma Co., Ltd. announced that it expects to receive KRW 110.00001 billion in funding from SK Discovery Co., Ltd., TiumBio Co., Ltd., and another investor	28/07/21
TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index	22/06/20
TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.	21/11/19
TiumBio Co. Ltd. has filed an IPO.	24/06/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TiumBio Co., Ltd.

Actions

A321550

KR7321550006

Autres langues

Filtres